Articles tagged with Immunology
Copper metabolism plays a crucial role in inflammatory bone diseases, with copper overload suppressing glycogen synthesis and increasing inflammatory activity. Researchers found that cuproptosis, a form of programmed cell death, can lead to bone weakening and osteoclast formation, providing a potential new therapeutic target.
Research reveals that salivary bacteria from gum disease alter gut metabolism, driving osteoclast activity and systemic bone loss. Microbial metabolites like indole-3-lactic acid inhibit osteoclast differentiation and activity.
Researchers identified molecular defect in taste receptor cells due to reduced levels of PLCβ2 protein, which strengthens the signal before transmission to the brain. Taste cells that detect salty and sour flavors are less affected.
The James P. Allison Institute at UT MD Anderson Cancer Center appoints Eric Gardner, Betty Kim, Rodrigo Romero, and Hojong Yoon to advance immunotherapy research. These experts bring expertise in immune therapy resistance, cancer vaccines, bioengineering, tumor evolution, and drug development.
New MSK research reveals that the TCA cycle's waste-management function may present an opportunity against cancer, microplastics impair immune 'housekeeping' functions and TOX plays different roles in different immune cells. A new combination approach for treating advanced kidney cancer after immunotherapy has also been identified.
Researchers found that early precancerous cells in pancreas gather into specific clusters and interact with immune cells, weakening the body's ability to fight them. The study provides fresh insight into how pancreatic cancer may begin taking shape years before it is clinically detected.
A recent study led by Virginia Tech researchers found that certain medium-chain fats in infant formulas can strain the developing liver and lead to early signs of steatotic liver disease. Newborn pigs fed with these formulas accumulated liver fat faster than those fed long-chain fats, despite receiving the same calories and protein.
The Alliance for Clinical Trials in Oncology will host a webinar highlighting recent clinical advances in breast cancer, multiple myeloma, and leukemia. Researchers will present key findings from ASH and SABCS meetings, impacting treatment outcomes.
New CAR T cells engineered to detect low levels of CD70 show promise in eradicating kidney, ovarian, and pancreatic tumors in preclinical models. This breakthrough provides a potential strategy for treating multiple solid tumor types with targeted immunotherapy.
Immune cells have been found to selectively extract nuclear DNA from dying cells, a regulated cellular function that challenges traditional views of the nucleus. This discovery, known as nucleocytosis, may hold implications for understanding autoimmune diseases, infections, and cancer, as well as informing drug development strategies.
Researchers at UCLA have found a way to supercharge immune cells with a fuel source that tumors can't steal, dramatically improving their ability to survive and attack solid tumors. The approach enables T cells to import cellobiose and convert it into usable glucose inside the cell.
The project aims to test whether reducing chronic inflammation triggered by DNA can help older adults stay healthier. The research focuses on retrotransposons, which become increasingly active with age, leading to tissue decline.
Researchers are developing an organ-on-a-chip platform to study immune rejection in pig-to-human liver transplantation, addressing a major hurdle in xenotransplantation. The project aims to generate data supporting future preclinical studies and bring xenotransplantation closer to clinical use.
Researchers at Sultan Qaboos University have identified three novel antimicrobial peptides from dromedary camels that effectively target multidrug-resistant bacteria. The peptides, CdPG-3 and CdCATH, demonstrate strong antibacterial activity across Gram-positive and Gram-negative bacteria.
A large registry study identifies a specific genetic mismatch linked to severe acute graft-versus-host disease (aGVHD) after cord blood transplantation, tripling the risk of life-threatening complications. Researchers found that a particular HLA combination in donors and recipients increased aGVHD risk by threefold.
Researchers have engineered a novel CAR-T cell that can be switched off on demand using a cancer drug, offering improved safety and efficacy. The new system, known as DROP-CAR-T, uses a clinically approved drug to disrupt tumor cell binding, preserving the cells for continued treatment.
A new Immunology Center will accelerate discoveries in muscle immunology and immune responses to gene therapies. Klaudia Kuranda brings expertise in immunology, onco-immunology, and leadership experience to the center.
The Michelson Medical Research Foundation has awarded $750,000 to five early-career scientists for their innovative work in immunology, vaccine discovery, and immunotherapy. The recipients will use the funding to accelerate their research and develop new treatments for diseases such as cancer and autoimmune disorders.
Researchers found that macrophages retain memories of previous infections due to persistent signaling molecules left behind, which can be reversed by blocking cytokine signaling pathways. This discovery suggests new ways to reduce the activity of misprogrammed macrophages contributing to autoimmune diseases.
Researchers developed a vascularized liver tissueoid-on-a-chip that recapitulates key structural, functional, and immunological features of human liver tissue. The platform enabled the study of liver regeneration and immune-mediated allograft rejection in a physiologically relevant human system.
A new UCLA study found that adding immunotherapy to standard chemotherapy before surgery is safe and shows promise for some patients with borderline-resectable pancreatic cancer. The combination treatment helped patients live long enough to reach surgery, shrank tumors, and produced encouraging survival outcomes.
A Cornell University study reveals that an existing FDA-approved drug, AMD3100, can prevent the sequestration of immune T cells from tumors, allowing them to attack cancer cells. The treatment shows promise for fibrolamellar carcinoma, a rare and fatal liver cancer with no cure.
The review outlines how vascular-immune crosstalk affects various diseases, revealing novel therapeutic opportunities. It highlights the shared embryonic origin of blood vessel cells and immune cells, as well as coordinated immune cell trafficking mechanisms.
Researchers developed an AI-driven pipeline to create functional intracellular antibodies, overcoming major barriers in intrabody development. The approach successfully redesigned structures compatible within the cellular environment, enabling high target specificity and stability.
Researchers at Ragon Institute discovered that antibodies produced in germinal centers act as a 'brake' on selection, redirecting the immune system toward broader protection. Stronger-binding B cells suppress weaker ones targeting the same site, establishing a localized feedback loop.
Scientists have identified a previously unknown cellular barrier in the brain called base barrier cells, which provides compartmentalization of the choroid plexus, brain, and cerebrospinal fluid. These cells become vulnerable during systemic inflammation, allowing harmful substances to enter the central nervous system.
Researchers studied 434 children for signs of autism or neurodevelopmental problems, finding no link between mRNA vaccine and autism. The study suggests that COVID-19 vaccines are safe to receive during pregnancy to protect maternal and infant health.
Researchers have developed a breakthrough technique to transform a patient's own T cells into soldiers trained to recognize and kill cancer cells, benefiting tens of thousands of individuals with blood cancers. The approach is now being explored for solid tumors and other diseases.
Researchers have discovered a new mechanism by which an existing cancer drug can block the loss of BCMA molecules on cancer cells, allowing CAR T cell therapy to become effective again in some patients. The study shows that carfilzomib can prevent the degradation of BCMA and restore its presence on the surface of malignant plasma cells.
A team from UNIGE has shown that certain antibodies to seasonal flu can also target avian flu. Stimulating these antibodies could strengthen protection in the event of a pandemic. Vaccinated individuals show increased levels of cross-reactive antibodies capable of neutralizing the H5N1 virus, which may result in milder symptoms.
A UCalgary study found that adding high doses of vitamin B3 to the treatment plan may help rejuvenate compromised immune cells to kill tumour cells. The clinical trial showed promising results, with 82% of participants free of cancer progression at six-months.
Researchers at Weill Cornell Medicine discovered that food shortages trigger a coordinated system to uphold immune function while conserving energy. Calorie-restricted mice fought off infection using very little glucose, thanks to glucocorticoids, which reorganized immune cells and their energy usage.
Halle Zhang joins Insilico Medicine to lead global clinical development strategy for the company's oncology portfolio. She brings over 20 years of experience in oncology clinical development and a track record of advancing therapies through registrational trials.
Researchers at MIT and Scripps Research Institute have developed a vaccine that generates a significant population of rare precursor B cells capable of evolving to produce broadly neutralizing antibodies against HIV. The DNA-VLP approach shows potential for inducing broadly neutralizing antibody responses against influenza as well.
Researchers at Salk Institute uncover two transcription factors, ZSCAN20 and JDP2, that determine T cell fate. Turning off these genes reverses T cell exhaustion and restores their ability to kill tumors without losing immune memory. The study challenges the long-standing belief of inevitable immune exhaustion.
Researchers aim to develop a blood test that can determine a person's entire infection history by analyzing T-cell receptor analysis and sequencing. This could provide an indication of which pathogens they are immune to, improving diagnosis and treatment.
Researchers have designed antibodies that recognize a unique sugar found on bacterial cells, providing a potential new treatment for multidrug-resistant hospital-acquired infections. The target of the antibody is pseudaminic acid, a sugar molecule produced exclusively by bacteria and used to evade immune responses.
A study published in Microbiome found that gut microbiome-derived butyrate activates immune cells to enhance vaccine efficacy by promoting T follicular helper (Tfh) cell activity and mucosal antibody production. This discovery highlights the crucial role of gut environment regulation in controlling infections and enhancing vaccine resp...
A new UCLA study clarifies the complex relationship between antibody-driven immunity, viral evolution, and disease severity in SARS-CoV-2. The research found that population-wide antibody responses exert a powerful selective pressure driving the virus to mutate and evade detection.
Engineered yeast cells can mimic real cancer cells and be used to test new cancer immunotherapies much faster and cheaper than before. This new technology enables researchers to assess which CAR T variants are most promising much more quickly, leading to safer and more targeted cancer treatments.
Researchers from Memorial Sloan Kettering Cancer Center reveal the origins of Thetis cells, which play a crucial role in teaching immune system tolerance. The team used single-nucleus DNA sequencing to shed light on pancreatic cancer evolution and identify genetic changes that occur earlier or later in disease progression.
University of Toronto researchers highlight the importance of studying child obesity, gut bacteria, and metabolic conditions to prevent youth-onset diabetes. They emphasize the need for personalized interventions tailored to individual microbiome profiles.
Chronic cellular stress drives liver cell cancer growth, suppressing immune response. Activated ATF6α makes tumors responsive to immunotherapy, opening up new therapeutic approaches.
A new experimental intranasal spray, INNA-051, will be tested in a randomized Phase 2 trial to determine its safety and effectiveness in reducing illness from respiratory viruses. The study aims to enroll 1,100 healthy adults at increased risk of upper respiratory virus infections.
A new platform developed by VIB and UGent researchers allows for more accurate prediction of antibody drug effects in humans. The platform uses a next-generation mouse model that closely reflects human immune biology, enabling better decisions early in drug development.
Researchers developed new chemical probes to track individual enzymes, enabling direct measurement of protein activity and correcting prior limitations. This allows for a clearer picture of molecular logic in cells undergoing programmed cell death, potentially informing drug discovery.
A big data study has identified a specific molecular state of immune cells as associated with the severity of fatigue and respiratory symptoms in Long COVID patients. This finding offers exciting starting points for further research into genetic risk factors and individualised medicine.
Researchers identified statins as a potential booster for cancer immunotherapy by preventing the release of PD-L1-containing sEVs. Statin treatment suppressed UBL3 modification, reduced PD-L1 sorting into sEVs, and improved survival outcomes in lung cancer patients.
Researchers at Salk Institute debut an epigenetic catalog that shows genetic inheritance and life experiences have distinct effects on various types of immune cells, shedding light on individual differences in immune responses and potential new personalized therapeutics.
Researchers have uncovered a new understanding of how cardiac events are interconnected with the brain and nervous/immune systems. They found that sensory neurons in the vagus nerve detect injury and transfer signals to dedicated brain structures, leading to activation of the immune system.
Researchers identified Fab antibody fragments that target the IgE Cε2 domain, effectively stripping IgE from mast cells. The most potent Fab clones showed rapid efficacy in cellular assays and in vivo anaphylaxis models, demonstrating potential as a next-generation anti-allergy therapy.
The cGAS-STING pathway plays a crucial role in detecting cellular DNA, triggering type I interferons and cytokines, and modulating immune responses. Its therapeutic potential is being explored in cancer and various diseases, with promising preclinical evidence suggesting its potential as a target for next-generation immunotherapies.
Salk Institute scientists discover that dietary supplementation of the amino acid methionine protects infected mice against inflammation-related wasting, blood-brain barrier dysfunction, and death. Methionine boosts kidney filtration, reducing circulating cytokine levels and improving disease outcomes.
Researchers found that TL1A, a key immune signaling protein, stimulates the growth of new white blood cells in the bone marrow, which then promote tumor formation in the gut. The study suggests that blocking TL1A activity could be an effective strategy to treat IBD and prevent associated colorectal tumors.
The University of Texas MD Anderson Cancer Center has made significant advancements in cancer care through its collaborative efforts between clinicians and scientists. These breakthroughs include an immune-targeting vaccine that shows promise in intercepting cancer in patients with Lynch Syndrome, a novel immunotherapy that demonstrate...
Researchers at the University of Missouri are developing AI models to accurately detect melanoma by analyzing images of skin abnormalities. The technology can help dermatologists identify cases that may require closer attention, leading to earlier treatment and improved health outcomes.
Researchers identified a distinct population of activated CD38+ HLA-DR+ CD8+ T cells that expands in patients at risk for acute graft-versus-host disease (aGVHD). Tracking this subset can predict disease onset and guide treatment, with targeted therapy offering a promising avenue for precise intervention.
Researchers found identical bacterial strains in the mouth and gut of patients with advanced chronic liver disease, suggesting oral bacteria colonize the gut. These bacteria can damage the intestinal barrier, compromising gut health.
Salk Institute scientists found distinct disease courses and tolerance mechanisms in younger and older mice with sepsis, indicating a need for age-tailored therapies. The study suggests that future treatments may focus on controlling infection-generated damage rather than just targeting the pathogen.